Sensuous Pharmaceuticals Private Limited
Pharmaceutical trading company based in Assam, established in 2020.
2020 | Cachar, Assam (India) | Active
Sensuous Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 5 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 54.40%
- Profit Growth -326.57%
- Ebitda -214.12%
- Net Worth -57.66%
- Total Assets 1331.24%
About Sensuous Pharmaceuticals
Sensuous Pharmaceuticals Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 20 January 2020 (Five years and one month 7 days old ). Its registered office is in Cachar, Assam, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Samar Ghosh and Sumita Das serve as directors at the Company.
Company Details
- Location
Cachar, Assam, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24100AS2020PTC019846
- Company No.
019846
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Jan 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Shillong
Industry
Pharma
Who are the key members and board of directors at Sensuous Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Samar Ghosh  | Director | 20-Jan-2020 | Current |
| Sumita Das | Director | 29-May-2021 | Current |
Financial Performance of Sensuous Pharmaceuticals.
Sensuous Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 54.4% increase. The company also saw a substantial fall in profitability, with a 326.57% decrease in profit. The company's net worth observed a substantial decline by a decrease of 57.66%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sensuous Pharmaceuticals?
In 2022, Sensuous Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sensuous Pharmaceuticals?
Unlock and access historical data on people associated with Sensuous Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sensuous Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sensuous Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
